6/16/2020 8:08:53 AM
AgeX Therapeutics And Pluristyx Enter Manufacturing, Marketing,
and Distribution Agreement
6/2/2020 8:06:42 AM
AgeX Therapeutics And ImStem Biotechnology Sign Non-Binding LoI For IMS001 For COVID-19 And Other Causes Of ARDS
5/29/2020 8:04:42 AM
AgeX Therapeutics And Sernova Announce Research Collaboration
5/21/2020 8:33:44 AM
AgeX Therapeutics Appoints Andrea Park As CFO
5/14/2020 4:07:29 PM
AgeX Therapeutics Q1 Loss/share $0.08 Vs. Loss $0.09 Year Ago
5/1/2020 8:57:45 AM
AgeX Therapeutics Reports Reduction In Projected Cash Expenditures
3/20/2020 9:14:02 AM
AgeX Therapeutics Licensee ImStem Announces FDA Has Lifted Hold And Cleared Investigational NDA For IMS001
2/3/2020 8:07:30 AM
AgeX Therapeutics Announces Research Collaboration With The University Of California, Irvine
12/26/2019 8:02:24 AM
AgeX Therapeutics Announces Drawdown Of $1.3 Mln Of Second Tranche Of Loan Facility From Juvenescence
12/10/2019 8:04:07 AM
AgeX, Lineage Cell Therapeutics Report Issuance Of U.S. Patent For Method Of Generating Induced Pluripotent Stem Cells
12/9/2019 7:04:57 AM
AgeX Therapeutics Issues Year-End Letter To Shareholders Regardings Current Initiatives And Future Plans
11/14/2019 4:12:24 PM
AgeX Therapeutics Q3 Loss Per Share $0.09 Vs Loss $0.06 Last Year